BioMarin Pharmaceutical Given New $74.00 Price Target at UBS AG (BMRN)
Equities researchers at UBS AG raised their target price on shares of BioMarin Pharmaceutical (NYSE:BMRN) from $73.00 to $74.00 in a research report issued on Friday, AnalystRatings.Net reports. UBS AG’s target price suggests a potential upside of 22.70% from the company’s current price.
BioMarin Pharmaceutical (NYSE:BMRN) traded down 4.33% on Friday, hitting $57.70. The stock had a trading volume of 3,567,833 shares. BioMarin Pharmaceutical has a one year low of $53.53 and a one year high of $84.25. The stock has a 50-day moving average of $65.88 and a 200-day moving average of $69.11. The company’s market cap is $8.287 billion.
BMRN has been the subject of a number of other recent research reports. Analysts at Nomura cut their price target on shares of BioMarin Pharmaceutical from $81.00 to $77.00 in a research note on Friday. Separately, analysts at Wedbush raised their price target on shares of BioMarin Pharmaceutical from $74.00 to $76.00 in a research note on Tuesday, March 25th. Finally, analysts at Goldman Sachs downgraded shares of BioMarin Pharmaceutical from a “buy” rating to a “neutral” rating in a research note on Tuesday, March 25th. They now have a $84.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. BioMarin Pharmaceutical has a consensus rating of “Buy” and an average price target of $77.67.
BioMarin Pharmaceutical Inc (NYSE:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.